Eris Lifesciences enters licensing deal with Biocon for insulin glargine

The launch of long acting insulin glargine will help Eris to fill the gap in its insulin portfolio. Eris derives more than half of its revenues from cardio-metabolic therapeutic segment, and has adopted a